variation of mannitol dose
ApprovedSmall molecule
variation of mannitol dose is one of 11 small molecule programs targeting Intracranial Hypertension. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Intracranial Hypertension
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Osmitrol
BB. Braun Medical Inc.
Approved
Ozempic
Novo NordiskPhase 3
Pentothal
AAbbott
Phase 3
Cisatracurium Besilate
UUniversity Hospital, Clermont-Ferrand
Approved
Diamox
TevaPhase 1
variation of mannitol dose
UUniversity Hospital, Grenoble
Approved
Pentobarbital
UUniversity of California, Los Angeles
Phase 3
AZD4017
AstraZenecaPhase 2
Nacl
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for variation of mannitol dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Grenoble